Author

Peter Irving 1

1 Guy´s and St Thomas´ Hospital Dept. of Gastroenter

A NOVEL ORAL DOMAIN ANTIBODY TO TUMOUR NECROSIS FACTOR (TNF), ENGINEERED TO BE STABLE TO INTESTINAL PROTEASES, RESULTS IN HIGH CONCENTRATIONS OF ACTIVE COMPOUND DETECTED IN FAECES OF CROHN’S PATIENTS AFTER ORAL DOSING

Jan Robinson, Scott Crowe, Mike West, Tim Carlton, Luana Maggiore, Gary Whale, James Ritter, Peter Irving, Suhail Nurbhai

A PROTEASE-STABILISED ORAL DOMAIN ANTIBODY TO TNF DELIVERS HIGH CONCENTRATIONS OF ACTIVE COMPOUND IN ILEAL FLUID OF SUBJECTS WITH AN ILEOSTOMY

Jan Robinson, Scott Crowe, Gary Whale, Kevin Roberts, Mike West, James Ritter, Peter Irving, Suhail Nurbhai

Correlation of vedolizumab trough levels with clinical and biochemical markers in inflammatory bowel disease

Aravind Gokul Tamilarasan, Antonio Guerrero, Laura Arias, Megan Burns, Zehra Arkir, Susanna Meade, Peter Irving

COST-UTILITY OF BIOSIMILAR INFLIXIMAB (INFLECTRA©) FOR THE TREATMENT OF LUMINAL CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Fanni Rencz, Valentin Brodszky, Petra Baji, Marta Pentek, Laszlo Gulacsi, Petra Anna Golovics, Zsuzsanna Vegh, Krisztina Barbara Gecse, Silvio Danese, Peter Irving, Peter L Lakatos

COST-UTILITY OF BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF FISTULISING CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Petra Baji, Marta Pentek, Valentin Brodszky, Laszlo Gulacsi, Fanni Rencz, Petra Anna Golovics, Krisztina Barbara Gecse, Zsuzsanna Vegh, Silvio Danese, Peter Irving, Peter L Lakatos

DIFFUSION WEIGHTED MRI OF INFLAMMATORY BOWEL DISEASE

Sarah Aurakzai, Sofia Gourtsoyianni, Simon H. Anderson, Peter Irving, Vicky Goh, Nyree Griffin, Jeremy Sanderson

Early 'Real World' Experience with Tofacitinib for Moderate to Severe Ulcerative Colitis

Sailish Honap, Esha Sharma, Shuvra Ray, Yesmina Begum, Aravind Gokul Tamilarasan, Georgina Cunningham, Raphael Luber, Joel Mawdsley, Simon H. Anderson, Jeremy Sanderson, Peter Irving

EARLY RELAPSE OF ULCERATIVE COLITIS AFTER DISCONTINUATION OF TREATMENT IN PATIENTS RESPONDING TO GOLIMUMAB 

P. John Hamlin, Shaji Sebastian, Peter Irving, Daniel R. Gaya, Colin Wheeler, Anita Rose, Gillian Gillespie, Chris S. J. Probert

Early Use to Long Term Management with Vedolizumab: A Spotlight on UC (Takeda Pharmaceuticals International AG)

Pierre Michetti, Peter Irving, Edouard Louis

GO-COLITIS 6-WEEK INDUCTION PATIENT-REPORTED OUTCOMES OF PARTIAL MAYO SCORE RESULTS

Shaji Sebastian, Chris S. J. Probert, Daniel R. Gaya, Peter John Hamlin, Peter Irving, Gillian Gillespie, Helen Tate, Colin Wheeler

Item 1 - 10 / 55
1
2 3 4 5 6